Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS

[1] Ciardiello F(2008)EGFR antagonists in cancer treatment N Engl J Med 358 1160-1174

[2] Tortora G(2004)Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337-345

[3] Cunningham D(2007)Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 67 2643-2648

[4] Humblet Y(2011)Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥2 line cetuximab-based therapy of colorectal cancer patients PLoS ONE 6 e15980-1169

[5] Siena S(2007)Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy Br J Cancer 96 1166-3995

[6] Khayat D(2006)KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 3992-762

[7] Bleiberg H(2010)Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 753-1261

[8] Santoro A(2012)Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study J Transl Med 10 87-1857

[9] Benvenuti S(2010)Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer J Clin Oncol 28 1254-2629

[10] Sartore-Bianchi A(2009)PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies Cancer Res 69 1851-472

[1] Ciardiello F(2008)EGFR antagonists in cancer treatment N Engl J Med 358 1160-1174

[2] Tortora G(2004)Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337-345

[3] Cunningham D(2007)Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 67 2643-2648

[4] Humblet Y(2011)Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥2 line cetuximab-based therapy of colorectal cancer patients PLoS ONE 6 e15980-1169

[5] Siena S(2007)Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy Br J Cancer 96 1166-3995

[6] Khayat D(2006)KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 3992-762

[7] Bleiberg H(2010)Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 753-1261

[8] Santoro A(2012)Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study J Transl Med 10 87-1857

[9] Benvenuti S(2010)Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer J Clin Oncol 28 1254-2629

[10] Sartore-Bianchi A(2009)PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies Cancer Res 69 1851-472